[go: up one dir, main page]

AU2001236266B2 - Use of a compound for preparing a drug - Google Patents

Use of a compound for preparing a drug Download PDF

Info

Publication number
AU2001236266B2
AU2001236266B2 AU2001236266A AU2001236266A AU2001236266B2 AU 2001236266 B2 AU2001236266 B2 AU 2001236266B2 AU 2001236266 A AU2001236266 A AU 2001236266A AU 2001236266 A AU2001236266 A AU 2001236266A AU 2001236266 B2 AU2001236266 B2 AU 2001236266B2
Authority
AU
Australia
Prior art keywords
group
positions
lower alkyl
iodine
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001236266A
Other versions
AU2001236266A1 (en
Inventor
Jan Bergman
Lennart Moller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OxyPharma AB
Original Assignee
OxyPharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by OxyPharma AB filed Critical OxyPharma AB
Publication of AU2001236266A1 publication Critical patent/AU2001236266A1/en
Assigned to OXYPHARMA A.B. reassignment OXYPHARMA A.B. Request for Assignment Assignors: LUNDBLAD, LEIF
Application granted granted Critical
Publication of AU2001236266B2 publication Critical patent/AU2001236266B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Use of a compound of formula (I) wherein R1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R1 can be a hydroxyl group; X is a group -(CH2)n-R2, wherein R2 represents a nitrogen containing basic residue such as NH2, NHR4 or NR5R6, wherein R4, R5 and R6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide, for preparing a drug for treatment of MS (multiple sclerosis).

Description

WO 01/60371 PCT/SE01/00326 USE OF A COMPOUND FOR PREPARING A DRUG.
The present invention relates to the use of a compound of the general formula I 11 1 1 7
R
N
7 5 4 7 x for preparing a drug for treatment of MS (multiple sclerosis).
MS is a chronic disease with its origin in the central nervous system (CNS) that often leads to severe consequences. MS can be mild with minor symptoms to severe paralysis and loss of vision. The diagnosis is most common between the ages of 20 to 40 and thereafter the disease continues the remaining life span. Sometimes MS develops rapidly, while in other cases the afflicted persons can live for many decades only with some disabilities.
MS is more frequent at northern latitudes. Depending on region in the western world the prevalence varies with 50-150 cases per 100,000. In the US only, some 250,000-350,000 have the MS diagnosis. Females have a double risk, compared to males, to develop MS.
WO 01/60371 PCT/SE01/00326 2 It is generally accepted that the immune defense of a patient with MS attacks the CNS, while the exact mechanisms are unknown. Due to inflammation of the nerve isolation (myeline) there are dysfunctions and short-circuits of nerve fibers and thereby effects on the muscles controlled by these nerves.
The treatment of MS is focused on the reduction of symptoms. To cure or stop the MS disease is not possible with today's knowledge. Consequently there does not exist any drug to cure or delay onset of the disease.
Treatments used are: #Transplantation of bone marrow and treatment of cytostatics and lifelong administration of immunosupressive drugs. This method could work for some patients but it is very expensive and includes several risks for the patient. Administration of cytostatics is still considered to be controversial in treatment of MS since the effects are unclear and potential side- effects are severe.
#There are two drugs used with the aim to cure or delay the MS disease; Interferon-beta (trademarks AvonexR and Betaseron R can reduce the symptoms among certain groups of patients and is therefore administered to most patients for ethical reasons. The effect is unclear for the population of MS patients and it is a very expensive treatment.
Glatiramer acetate (trademark Copaxone R) can for some patients reduce the frequence of attacks, but the side effects are substantial and there is a problem to distinguish the symptoms of the MS disease and side effects.
Today there does not exist an effective treatment for MS. The treatment is focused on reducing symptoms. Tests with transplantation and different P:\OPER\PDB\Spci\201236266 Ispa.doc-01/02/05 -3drug treatments to cure the disease have so far not shown any solutions. It can work for some patients, although there are risks, side effects and very high costs involved. MS is a rather common disease that appears early in life. In addition it is a life long disease with severe symptoms. The demand for drugs that can protect the MS patients for the severe development of the disease is therefore of high priority.
According to the present invention it has surprisingly been found that a substituted indoloquinoxaline of the following general formula I can be used for preparing a drug for treatment of MS.
The invention, in another aspect, provides a method for the treatment of MS comprising the administration of a compound of general formula I to a subject in need thereof.
The compound which according to the present invention is to be used for preparing a drug for treatment of MS is a compound of the following general formula I 11 1
IR
7 R x wherein RI represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 Ri can be a hydroxyl group; X is a group -(CH 2 )n-R 2 wherein R 2 represents a nitrogen containing basic residue such as
NH
2 NHR4 or NR 5
R
6 wherein R4, R 5 and R 6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 WO 01/60371 PCT/SE01/00326 4 and R 3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine monobromide.
R1 is preferably selected from hydrogen and lower alkyl groups, especially methyl. More preferably R 1 is methyl in positions 2 and 3 and hydrogen in the other positions.
Suitable compounds are such compounds wherein Ri is hydroxy in one of the positions 7-10, especially in position 9.
The compounds used according to the present invention and their preparation are described in EP patent 0238459 and US patent 4,990,510 which are incorporated herein by reference.
A compound which has proven to be especially effective is the compound of the following formula II
CH
3
II
CHl{ CH 3 In the drawings: Figure 1 shows the results obtained in an EAE model test.
Figure 2 shows the results obtained in an EAE rat model test with different doses of a compound used according to the present invention.
Figure 3 shows the effect of pre-treatment with a compound used according to the present invention.
WO 01/60371 PCT/SE01/00326 Figure 4 shows the effect of after-treatment with a compound used according to the present invention.
The EAE (experimental autoimmune encephalomyelitis) model is a generally accepted animal model for the acute MS symptoms (1)Ruuls et al, J.
Immunology, 1996, 157, 5721-5731; (2)van der Medide et al, J.
Neuroimmunology, 1998, 84, 14-23; (3)Smith et al, Nature Medicine,2000, 6, 1, 62-66). The model is based on Lewis rats that day 0 are induced by pig myeline peptide (MBP 68-86) och 2 mg of Myobacterium tuberculosis.
After one week severe CNS symptoms appear that are by double blind examination given a value a clinical score. The higher value, the more severe effect. The scale is 0-5. After some 14 days there is a peak in symptoms followed by a decline back to the normal situation.
The negative control has no treatment except the immunization (day 0) to induce the acute MS response. In Figure 1 the results from the negative control, Interferon-beta and a compound used according to the present invention, 2,3-dimethyl(dimethylaminoethyl)-5H-indolo-(2,3-b)quinoxaline, (B-220) are shown. From the figure it can be seen that Interferon-beta has no reducing effect of the CNS symptoms The lower curve represents the tested substance used according to the present invention, which substance surprisingly and unexpectedly reduces the CNS symptoms with 2/3.
In the test Interferon-beta was administered daily with 3 x 10 5 U/animal which is a medium dose The tested substance(B-220), was administered daily with 6 mg/animal, a dose that can be increased since the margin to toxic effects is wide and most likely further reduce the symptoms. It is to be noted that the acute toxicity of the tested substance used according to the present invention is low, which is exemplified with the following: WO 01/60371 PCT/SE01/00326 6
LD
5 0 oral, rat; >800 mg/k;g bw
LD
5 0 intravenous, rat; >100 mg/kg bw NOEL, intravenous, rat; 12.5 mg/kg bw NOEL, cutaneous, rabbit; 200 mg/kg bw (NOEL=No Observable Effect Level) The chronic toxicity has been tested up to 270 days on mice and the substance has not induced toxicity, on the contrary the substance has protected the animals for different health effects.
In the well established EAE rat model for multiple sclerosis (MS) a compound used according to the present invention, B-220, was shown to down-regulate the clinical symptoms (clinical score) in a dose dependent manner. The results are shown in Figure 2. At the highest dose, 12 mg/animal, (lower curve) the onset is delayed approximate 4 days, the recovery starts approximate 3 days earlier and the total effect is dramatically lowered. A majority.of the animals do not show any symptoms at all in this group. Symptom grading 1 is thus a very weak and mild effect while grading 3 is a severe paralysis. The intermediate curve illustrates a dose of 6 mg/animal and the onset is delayed approximate 2 days, the recovery starts approximate 2 days earlier and the total effect is substantially lower as compared to the control, highest curve, where no B-220 is added.
In Figure 3 pre-treatment with B-220 before the onset of the disease is shown. The highest curve is illustrating the control without any added B-220 while the lower curve is after administration of B-220 of 6 mg/animal. As seen from the Figure the pre-treatment results in a clear lowered and delayed MS effect. Administration of B-220 was from -7 to +7 days in relation to the onset of disease (day 0).
PAOPER\PDBMSp=iA2OOI236Z66 lspa.dc-Ol/O2/05 -7- In Figure 4 after-treatment with B-220 starting from day 7 from the time point when the disease was initiated (day 0) and throughout the experiment is shown wherein the highest curve is a control without any addition of B-220 and the lower curve is representing a dose of 6 mg/animal of B-220. As seen from the Figure the after-treatment with B-220 lowered the MS effect in the rats.
The vertical lines in both Figure 3 and Figure 4 represent mean±standard deviation.
A suitable dosage range for humans is 1 to 50 mg/kg body weight.
The reference to any prior art in this specification is not, and should not be taken as, an acknowledgment or any form of suggestion that that prior art forms part of the common general knowledge in Australia.
Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

Claims (13)

1. Use of a compound which is a substituted indoloquinoxaline of the general formula I 11 1 9 2 RN 1 7 <3x x wherein R 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R 1 can be a hydroxyl group; X is a group -(CH 2 )n-R 2 wherein R 2 represents a nitrogen containing basic residue such as NH 2 NHR4 or NR 5 R 6 wherein R4, Rs and R 6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R 3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine mono-bromide, for preparing a drug for treatment of multiple sclerosis.
2. Use according to claim 1 wherein R 1 is methyl in positions 2 and 3 and hydrogen in the other positions. P \OPER\PDB\Sp-cU2OO236266 kps doc.002J05 -9-
3. Use according to claim 1 or 2 wherein Ri in one of the positions 7-10 is hydroxy.
4. Use according to claim 3 wherein R 1 in position 9 is hydroxy.
5. Use according to any one of the preceding claims wherein X is CH 2 N(CH 3 2 and R 3 is hydrogen.
6. A method for the treatment of multiple sclerosis comprising the administration of a compound which is a substituted indoloquinoxaline of the general formula I 11 1 2 7 1 R x wherein R 1 represents hydrogen or one or several, preferably 1 to 4, similar or different substituents in the positions 1-4 and/or 7-10, selected from halogen, preferably Br, lower alkyl/alkoxy group having not more than 4 carbon atoms, trifluoromethyl group, trichloromethyl group; and in one of the positions 7-10 R 1 can be a hydroxyl group; X is a group -(CH 2 )n-R 2 wherein R 2 represents a nitrogen containing basic residue such as NH 2 NHR4 or NR 5 R 6 wherein R 4 R 5 and R 6 independently are lower alkyl or cycloalkyl and n is an integer of from 1 to 4 and R 3 represents hydrogen, lower alkyl/cycloalkyl group having not more than 4 carbon atoms, and the physiologically acceptable addition products of the compounds with acids and halogen adducts, preferably adducts with iodine, iodine monochloride or iodine mono-bromide, to a subject in need thereof. P:\OPER\PDB\Spci201236266 Ispa.doc-01/02/05
7. The method according to claim 1 wherein R 1 is methyl in positions 2 and 3 and hydrogen in the other positions.
8. The method according to claim 1 or 2 wherein R 1 in one of the positions 7-10 is hydroxy.
9. The method according to claim 8 wherein R 1 in position 9 is hydroxy.
The method according to any one of claims 6-9 wherein X is CH 2 N(CH 3 2 and R 3 is hydrogen.
11. The method according to any one of claims 6-10 wherein the subject is a human.
12. Use of a substituted indoloquinoxaline substantially as hereinbefore described and/or exemplified.
13. A method for the treatment of multiple sclerosis substantially as hereinbefore described and/or exemplified. DATED this 31st day of January, 2005 OxyPharma A.B. By DAVIES COLLISON CAVE Patent Attorneys for the Applicant
AU2001236266A 2000-02-18 2001-02-16 Use of a compound for preparing a drug Ceased AU2001236266B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0000537-1 2000-02-18
SE0000537A SE516067C2 (en) 2000-02-18 2000-02-18 Use of a compound for the manufacture of a medicament
PCT/SE2001/000326 WO2001060371A1 (en) 2000-02-18 2001-02-16 Use of a compound for preparing a drug

Publications (2)

Publication Number Publication Date
AU2001236266A1 AU2001236266A1 (en) 2001-11-08
AU2001236266B2 true AU2001236266B2 (en) 2005-03-17

Family

ID=20278504

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001236266A Ceased AU2001236266B2 (en) 2000-02-18 2001-02-16 Use of a compound for preparing a drug
AU3626601A Pending AU3626601A (en) 2000-02-18 2001-02-16 Use of a compound for preparing a drug

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3626601A Pending AU3626601A (en) 2000-02-18 2001-02-16 Use of a compound for preparing a drug

Country Status (14)

Country Link
EP (1) EP1261344B1 (en)
JP (1) JP2003522792A (en)
CN (1) CN1192777C (en)
AT (1) ATE269083T1 (en)
AU (2) AU2001236266B2 (en)
CA (1) CA2400236C (en)
DE (1) DE60103857T2 (en)
ES (1) ES2222981T3 (en)
HU (1) HUP0204547A3 (en)
NO (1) NO323783B1 (en)
RU (1) RU2266117C2 (en)
SE (1) SE516067C2 (en)
WO (1) WO2001060371A1 (en)
ZA (1) ZA200206733B (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE527639C2 (en) * 2004-06-17 2006-05-02 Oxypharma Ab Alkyl-substituted indoloquinoxalins
DE602008001795D1 (en) 2008-04-30 2010-08-26 Univ Duisburg Essen IndolÄ2,3-bÜ, IndenÄ1,2-bÜ- and indenÄ2,1-bpyridoÄ2,3-fÜ Quinoxaline-3-carboxylic acids and esters, process for their preparation and their use as antiviral and antitumor agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8600260D0 (en) * 1986-01-21 1986-01-21 Lundblad Leif SUBSTITUTED INDOLOKINOXALINES
US5310732A (en) * 1986-02-03 1994-05-10 The Scripps Research Institute 2-halo-2'-deoxyadenosines in the treatment of rheumatoid arthritis

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
references cited in WO 01/60371 *

Also Published As

Publication number Publication date
HUP0204547A2 (en) 2003-04-28
CN1404393A (en) 2003-03-19
NO20023892L (en) 2002-08-16
NO20023892D0 (en) 2002-08-16
SE0000537L (en) 2001-08-19
JP2003522792A (en) 2003-07-29
NO323783B1 (en) 2007-07-09
ATE269083T1 (en) 2004-07-15
CN1192777C (en) 2005-03-16
RU2266117C2 (en) 2005-12-20
RU2002124771A (en) 2004-03-10
EP1261344B1 (en) 2004-06-16
ZA200206733B (en) 2003-08-22
DE60103857T2 (en) 2005-07-14
WO2001060371A1 (en) 2001-08-23
ES2222981T3 (en) 2005-02-16
SE0000537D0 (en) 2000-02-18
HUP0204547A3 (en) 2006-01-30
DE60103857D1 (en) 2004-07-22
EP1261344A1 (en) 2002-12-04
CA2400236C (en) 2009-09-22
CA2400236A1 (en) 2001-08-23
SE516067C2 (en) 2001-11-12
AU3626601A (en) 2001-08-27

Similar Documents

Publication Publication Date Title
US4507323A (en) Treatment of psychosexual dysfunctions
CA2339934C (en) Medicine for multiple sclerosis
Mamo Treatment of Behçet disease with chlorambucil: A follow-up report
US6903100B2 (en) Use of regularly scheduled high dose intravenous methotrexate therapy, with interim administration of immunomodulatory agents, to treat multiple sclerosis and other diseases of the central nervous system
US4438138A (en) Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone
KR20200077542A (en) Delayed-release deferiprone tablets and methods of use thereof
Nix et al. Effect of lomefloxacin on theophylline pharmacokinetics
KR19990072798A (en) Method of treating impotence due to spinal cord injury
AU2001236266B2 (en) Use of a compound for preparing a drug
JP2820737B2 (en) Substances for the treatment of male disability
US6333327B2 (en) Method for the treatment of Multiple Sclerosis
JP3415643B2 (en) Drugs for muscular dystrophy
US4840952A (en) Method for treatment of male impotence
WO2002094199A3 (en) METHOD OF INCREASING ANTI-NeuGc ANTIBODY LEVELS IN BLOOD
US4687771A (en) Method for treatment of male impotence
Bergen Jr et al. Hypocholesteremic effect in man of benzmalecene: An inhibitor of cholesterol biosynthesis
Reid Antivenene reaction following accidental sea-snake bite
JP2001526217A (en) Novel use of local anesthetics for vascular headache
JP2554819B2 (en) Synergists and pharmaceutical compositions in the treatment of anxiety
EP0005074A1 (en) A material and composition for reducing blood pressure
US9192602B2 (en) Indication of anthra[2,1,c][1,2,5]thiadiazole-6,11-dione compound in alleviating pain
JPH0656661A (en) Anticataract agent
RU1803119C (en) Method of extrauterine pregnancy treatment
US6476072B1 (en) Method of treating menstrual pain by enhancing the effectiveness of the human immune system
RU1814073C (en) Method of preventing keratotransplant rejection crisis

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: OXYPHARMA A.B.

Free format text: FORMER APPLICANT(S): LUNDBLAD, LEIF

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired